Although HIF-1 and PI3K pharmacological inhibition showed benefits in the inhibition of angiogenesis, invasiveness, proliferation, de-differentiation, and tumor growth in several solid tumors, their clinical use has demonstrated poor effectiveness due to low specificity and toxic side effects [30,50]. This evidence concerns the gene HIF1A and neoplasm.